×
Entrez Id:
23389
Gene Symbol:
MED13L
MED13L
0.700
CausalMutation
disease
CLINVAR
De novo genic mutations among a Chinese autism spectrum disorder cohort.
27824329
2016
×
Entrez Id:
23389
Gene Symbol:
MED13L
MED13L
0.700
GeneticVariation
disease
CLINVAR
Dosage changes of MED13L further delineate its role in congenital heart defects and intellectual disability.
23403903
2013
×
Entrez Id:
23389
Gene Symbol:
MED13L
MED13L
0.700
GeneticVariation
disease
UNIPROT
Missense mutations and gene interruption in PROSIT240, a novel TRAP240-like gene, in patients with congenital heart defect (transposition of the great arteries).
14638541
2003
×
Entrez Id:
23389
Gene Symbol:
MED13L
MED13L
0.700
Biomarker
disease
CTD_human
×
Entrez Id:
23389
Gene Symbol:
MED13L
MED13L
0.700
Biomarker
disease
GENOMICS_ENGLAND
×
Entrez Id:
3339
Gene Symbol:
HSPG2
HSPG2
0.200
Biomarker
disease
MGD
Role of collagen type II and perlecan in skeletal development.
12814946
2003
×
Entrez Id:
3339
Gene Symbol:
HSPG2
HSPG2
0.200
Biomarker
disease
MGD
Development of the coronary arteries in a murine model of transposition of great arteries.
12818570
2003
×
Entrez Id:
3339
Gene Symbol:
HSPG2
HSPG2
0.200
Biomarker
disease
MGD
Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice.
12142349
2002
×
Entrez Id:
1856
Gene Symbol:
DVL2
DVL2
0.200
Biomarker
disease
MGD
Dishevelled 2 is essential for cardiac outflow tract development, somite segmentation and neural tube closure.
12421720
2002
×
Entrez Id:
3339
Gene Symbol:
HSPG2
HSPG2
0.200
Biomarker
disease
MGD
Perlecan maintains the integrity of cartilage and some basement membranes.
10579729
1999
×
Entrez Id:
55997
Gene Symbol:
CFC1
CFC1
0.200
Biomarker
disease
MGD
A role of the cryptic gene in the correct establishment of the left-right axis.
10574770
1999
×
Entrez Id:
653275
Gene Symbol:
CFC1B
CFC1B
0.200
Biomarker
disease
MGD
A role of the cryptic gene in the correct establishment of the left-right axis.
10574770
1999
×
Entrez Id:
6899
Gene Symbol:
TBX1
TBX1
0.010
Biomarker
disease
BEFREE
At last MUGA follow-up: 6 (33%) cc-TGA /14 (36%) d-TGA patients showed a significant decline in sRVEF (>5%); 6 (33%) cc-TGA /17 (44%) d-TGA patients had a significant increase in sRVEDVi; and 7 (39%) cc-TGA /19 (49%) PA-TGA patients had a significant increase in sRVESVi.
28818352
2017